SGLT2i for Mitral Regurgitation; Mining Angiograms With AI; Melatonin and CVD Risk?

MedPage Today) — The Apple Watch atrial fibrillation feature got added to FDA’s list of qualified devices for use in clinical studies. (Mashable)
The SGLT2 inhibitor ertugliflozin (Steglatro) showed promise for the reduction of functional mitral…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button